169 related articles for article (PubMed ID: 34598710)
1. TTK is a potential therapeutic target for cisplatin-resistant ovarian cancer.
Liu Y; Zhu K; Guan X; Xie S; Wang Y; Tong Y; Guo L; Zheng H; Lu R
J Ovarian Res; 2021 Oct; 14(1):128. PubMed ID: 34598710
[TBL] [Abstract][Full Text] [Related]
2. TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway.
Qi G; Ma H; Li Y; Peng J; Chen J; Kong B
Cell Death Dis; 2021 Dec; 12(12):1135. PubMed ID: 34876569
[TBL] [Abstract][Full Text] [Related]
3. FOXM1 Contributes to Chemotherapy Sensitivity in Cervical Cancer by Regulating TTK.
Tang Q; Xu A; Yang Y; Zhang Y; Sun J
Discov Med; 2023 Jun; 35(176):208-220. PubMed ID: 37272088
[TBL] [Abstract][Full Text] [Related]
4. TTK (threonine tyrosine kinase) regulates the malignant behaviors of cancer cells and is regulated by microRNA-582-5p in ovarian cancer.
Lu N; Ren L
Bioengineered; 2021 Dec; 12(1):5759-5768. PubMed ID: 34516342
[TBL] [Abstract][Full Text] [Related]
5. Mitotic checkpoint kinase Mps1/TTK predicts prognosis of colon cancer patients and regulates tumor proliferation and differentiation via PKCα/ERK1/2 and PI3K/Akt pathway.
Zhang L; Jiang B; Zhu N; Tao M; Jun Y; Chen X; Wang Q; Luo C
Med Oncol; 2019 Nov; 37(1):5. PubMed ID: 31720873
[TBL] [Abstract][Full Text] [Related]
6. DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 Signaling.
Li J; Pan C; Boese AC; Kang J; Umano AD; Magliocca KR; Yang W; Zhang Y; Lonial S; Jin L; Kang S
Clin Cancer Res; 2020 Jul; 26(14):3843-3855. PubMed ID: 32341033
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of
Tsai YM; Wu KL; Chang YY; Hung JY; Chang WA; Chang CY; Jian SF; Tsai PH; Huang YC; Chong IW; Hsu YL
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32121246
[TBL] [Abstract][Full Text] [Related]
8. TTK regulates proliferation and apoptosis of gastric cancer cells through the Akt-mTOR pathway.
Huang H; Yang Y; Zhang W; Liu X; Yang G
FEBS Open Bio; 2020 Aug; 10(8):1542-1549. PubMed ID: 32530571
[TBL] [Abstract][Full Text] [Related]
9. TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.
Maire V; Baldeyron C; Richardson M; Tesson B; Vincent-Salomon A; Gravier E; Marty-Prouvost B; De Koning L; Rigaill G; Dumont A; Gentien D; Barillot E; Roman-Roman S; Depil S; Cruzalegui F; Pierré A; Tucker GC; Dubois T
PLoS One; 2013; 8(5):e63712. PubMed ID: 23700430
[TBL] [Abstract][Full Text] [Related]
10. In-Silico Evaluation of Genetic Alterations in Ovarian Carcinoma and Therapeutic Efficacy of NSC777201, as a Novel Multi-Target Agent for TTK, NEK2, and CDK1.
Khedkar HN; Wang YC; Yadav VK; Srivastava P; Lawal B; Mokgautsi N; Sumitra MR; Wu ATH; Huang HS
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072728
[TBL] [Abstract][Full Text] [Related]
11. Expression and function analysis of mitotic checkpoint genes identifies TTK as a potential therapeutic target for human hepatocellular carcinoma.
Liang XD; Dai YC; Li ZY; Gan MF; Zhang SR; Yin-Pan ; Lu HS; Cao XQ; Zheng BJ; Bao LF; Wang DD; Zhang LM; Ma SL
PLoS One; 2014; 9(6):e97739. PubMed ID: 24905462
[TBL] [Abstract][Full Text] [Related]
12. TTK inhibitor promotes radiosensitivity of liver cancer cells through p21.
Zhang H; Yao W; Zhang M; Lu Y; Tang J; Jiang M; Mou X; You G; Liang X
Biochem Biophys Res Commun; 2021 Apr; 550():84-91. PubMed ID: 33689884
[TBL] [Abstract][Full Text] [Related]
13. Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer.
Thu KL; Silvester J; Elliott MJ; Ba-Alawi W; Duncan MH; Elia AC; Mer AS; Smirnov P; Safikhani Z; Haibe-Kains B; Mak TW; Cescon DW
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1570-E1577. PubMed ID: 29378962
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a potent and selective covalent threonine tyrosine kinase (TTK) inhibitor.
Sun Y; Chen Z; Liu G; Chen X; Shi Z; Feng H; Yu L; Li G; Ding K; Huang H; Zhang Z; Xu S
Bioorg Chem; 2024 Feb; 143():107053. PubMed ID: 38159497
[TBL] [Abstract][Full Text] [Related]
15. Threonine and tyrosine kinase may serve as a prognostic biomarker for gallbladder cancer.
Xie Y; Lin JZ; Wang AQ; Xu WY; Long JY; Luo YF; Shi J; Liang ZY; Sang XT; Zhao HT
World J Gastroenterol; 2017 Aug; 23(31):5787-5797. PubMed ID: 28883705
[TBL] [Abstract][Full Text] [Related]
16. TTK activates Akt and promotes proliferation and migration of hepatocellular carcinoma cells.
Liu X; Liao W; Yuan Q; Ou Y; Huang J
Oncotarget; 2015 Oct; 6(33):34309-20. PubMed ID: 26418879
[TBL] [Abstract][Full Text] [Related]
17. TTK/hMps1 participates in the regulation of DNA damage checkpoint response by phosphorylating CHK2 on threonine 68.
Wei JH; Chou YF; Ou YH; Yeh YH; Tyan SW; Sun TP; Shen CY; Shieh SY
J Biol Chem; 2005 Mar; 280(9):7748-57. PubMed ID: 15618221
[TBL] [Abstract][Full Text] [Related]
18. Key role of dual specificity kinase TTK in proliferation and survival of pancreatic cancer cells.
Kaistha BP; Honstein T; Müller V; Bielak S; Sauer M; Kreider R; Fassan M; Scarpa A; Schmees C; Volkmer H; Gress TM; Buchholz M
Br J Cancer; 2014 Oct; 111(9):1780-7. PubMed ID: 25137017
[TBL] [Abstract][Full Text] [Related]
19. miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin.
Guo P; Xiong X; Zhang S; Peng D
Oncol Rep; 2016 Dec; 36(6):3552-3558. PubMed ID: 27748936
[TBL] [Abstract][Full Text] [Related]
20. TTK Inhibitors as a Targeted Therapy for
Zaman GJR; de Roos JADM; Libouban MAA; Prinsen MBW; de Man J; Buijsman RC; Uitdehaag JCM
Mol Cancer Ther; 2017 Nov; 16(11):2609-2617. PubMed ID: 28751540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
